John Manusu
Amministratore Delegato presso PrIME Biologics Pte Ltd.
Profilo
John Manusu is currently the Managing Director and Director at PrIME Biologics Pte Ltd.
He previously worked as the Non-Executive Chairman at Memphasys Ltd.
from 2012 to 2013 and as a Director and Director-Investor Relations at Arturus Capital Ltd.
from 1987 to 2007.
Posizioni attive di John Manusu
| Società | Posizione | Inizio |
|---|---|---|
PrIME Biologics Pte Ltd.
 PrIME Biologics Pte Ltd. BiotechnologyHealth Technology PrIME Biologics Pte Ltd. develops disposable therapeutic plasma manufacturing process. Its process doubles product yields while increasing product safety and removing viruses, bacteria, endotoxins, and prions. The firm’s process reduces the time it takes to produce multiple plasma products from days to hours. The company is headquartered in Singapore. | Amministratore Delegato | 01/01/1985 |
Precedenti posizioni note di John Manusu
| Società | Posizione | Fine |
|---|---|---|
| MEMPHASYS | Presidente | 29/11/2013 |
Arturus Capital Ltd.
 Arturus Capital Ltd. Financial ConglomeratesFinance Arturus Capital Ltd. is an investment company that holds interests in mining and gas projects. The company was founded on May 31, 1972 and is headquartered in North Perth, Australia. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| MEMPHASYS | Health Technology |
| Aziende private | 2 |
|---|---|
Arturus Capital Ltd.
Arturus Capital Ltd. Financial ConglomeratesFinance Arturus Capital Ltd. is an investment company that holds interests in mining and gas projects. The company was founded on May 31, 1972 and is headquartered in North Perth, Australia. | Finance |
PrIME Biologics Pte Ltd.
PrIME Biologics Pte Ltd. BiotechnologyHealth Technology PrIME Biologics Pte Ltd. develops disposable therapeutic plasma manufacturing process. Its process doubles product yields while increasing product safety and removing viruses, bacteria, endotoxins, and prions. The firm’s process reduces the time it takes to produce multiple plasma products from days to hours. The company is headquartered in Singapore. | Health Technology |
- Borsa valori
- Insiders
- John Manusu
